Leverkusen, February 28, 2023 — The Bayer Group attained strong development in 2015, publishing substantially greater sales and profits. “2022 was a really effective year for Bayer regardless of the difficult environment. We had the ability to provide, even throughout these hard times, and satisfied the updated monetary targets we embeded in August,” stated Werner Baumann, Chairman of the Board of Management, at the business’s Financial News Conference on Tuesday. The business is active in the best fields, he stated. “Health and nutrition are essential human requirements. Our vision of Health for all, cravings for none is and will stay critically important, particularly in times like these.”
Group sales was available in at 50.739 billion euros in 2022, up 8.7 percent on a currency- and portfolio-adjusted basis (Fx & & portfolio adj.). EBITDA prior to unique products increased by 20.9 percent to 13.513 billion euros, and consisted of a favorable currency result of 429 million euros (2021: unfavorable currency result of 507 million euros). The EBITDA margin prior to unique products increased to 26.6 percent (2021: 25.4 percent). EBIT totaled up to 7.012 billion euros, and was for that reason more than two times as high as in the previous year. Earnings can be found in at 4.150 billion euros (2021: 1.000 billion euros), while core revenues per share increased by 22.0 percent to 7.94 euros.
Complimentary capital more than doubled versus the previous year, increasing to 3.111 billion euros. Net monetary debt totaled up to 31.809 billion euros since December 31, 2022, down 4.0 percent from year-end 2021. Money inflows from running activities and the sale of the Environmental Science Professional service were partly balanced out by money outflows for dividends and unfavorable currency results.
“These are great outcomes. Together with the Supervisory Board, we are for that reason proposing a dividend of 2.40 euros to the Annual Stockholders’ Meeting. This represents a 20 percent boost compared to the previous year,” stated Chief Financial Officer Wolfgang Nickl. With 982.42 million shares entitled to the dividend, the business is for that reason set to disperse an overall of 2.358 billion euros to investors for financial 2022 (financial 2021: 1.965 billion euros).
Crop Science accomplishes record sales and industry-leading margin
Sales in the farming service (Crop Science) advanced by 15.6 percent (Fx & & portfolio adj.) to a record 25.169 billion euros, with service up in all areas. Development was greatest at Herbicides (Fx & & portfolio adj. 43.9 percent), which saw sales increase in Latin and North America and in Europe/Middle East/Africa in specific thanks to greater rates, as supply for glyphosate-based items was tight. Sales at Corn Seed & & Traits increased 8.8 percent (Fx & & portfolio adj.) as the department increased its market share. Cost boosts in all areas more than balance out a reduction in acreages in North America and lower license incomes. Sales at Fungicides were up 5.2 percent (Fx & & portfolio adj.), with greater rates in the Latin America and Europe/Middle East/Africa areas in specific more than balancing out a decrease in volumes in North America. Sales at Soybean Seed & & Traits were level with the previous year, with service growing in Latin America however decreasing in North America due to lower volumes.
EBITDA prior to unique products at Crop Science advanced by 46.2 percent to 6.867 billion euros, primarily due to the considerable boost in sales. Revenues likewise took advantage of contributions from continuous performance programs and a favorable currency impact of 284 million euros (2021: unfavorable currency result of 387 million euros). By contrast, incomes were primarily reduced by a boost in the expense of products offered, which was mainly due to high inflation. The EBITDA margin prior to unique products increased by 4.1 portion indicate an industry-leading 27.3 percent.
Pharmaceuticals gain from brand-new items and Eylea ™
Sales of prescription medications (Pharmaceuticals) increased by 1.1 percent (Fx & & portfolio adj.) to 19.252 billion euros. Over half a billion euros in sales originated from the department’s brand-new items: the cancer drug Nubeqa ™ and Kerendia ™ for the treatment of persistent kidney illness related to type 2 diabetes. Sales of Nubeqa ™, for example, nearly doubled year on year. Strong development was likewise tape-recorded for the ophthalmology drug Eylea ™ (Fx & & portfolio adj. plus 9.2 percent) and in the radiology service, that includes the Gadovist ™